295. Paradoxically Elevated Levels of Tumour Necrosis Factor in Patients with Juvenile Idiopathic Arthritis on Etanercept
نویسندگان
چکیده
منابع مشابه
Tumour necrosis factor-α levels are elevated in adolescent patients with juvenile idiopathic arthritis on etanercept therapy
Methods Serum TNF-a was measured in samples derived from 200 adolescent and young adult patients with JIA attending the adolescent and young adult rheumatology clinic at University College London Hospital using a commercial enzyme linked immunosorbent assay (ELISA) kit (eBioscience). Samples were tested in duplicate. Median age at sampling and median disease duration were 18 years and 8 years 9...
متن کاملCirculating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis
AIM The relationship between tumour necrosis factor-alpha (TNF-α) and drug survival had not been studied in juvenile idiopathic arthritis (JIA), and there were no laboratory tests to predict the long-term efficacy of biological drugs for JIA. We studied whether serum levels of TNF-α, free or bound to etanercept, could predict long-term efficacy of etanercept in children with JIA. METHODS We i...
متن کاملEtanercept and urticaria in patients with juvenile idiopathic arthritis.
Etanercept, a tumor necrosis factor receptor p75 Fc fusion protein (TNFR:Fc; Enbrel), has preliminarily been shown to be effective in the management of methotrexate-resistant polyarticular juvenile idiopathic arthritis (JIA). Reported side-effects have been minor, for example injection site reactions and upper respiratory tract infections, not necessitating discontinuation of the medication (1,...
متن کاملAnti-tumour necrosis factor (anti-TNF) in the treatment of juvenile idiopathic arthritis-associated uveitis
Results Of the 16 patients, 10 were treated with etanercept (62.5%), 1 with adalimumab (6.25%), and 5 (31.2%) with infliximab. Notably, two cases of uveitis were associated with use of etanercept. In 5 patients (31.2%) the antiTNF was changed because of lack of efficacy and/or side effects to another one (in 4/5 adalimumab). Ten patients had a complicated uveitis (cataract in 5). The number of ...
متن کاملChallenges in the management of juvenile idiopathic arthritis with etanercept
Biologic agents have been designed with the help of immunological studies to target particular areas of the immune system which are thought to play a role in the pathogenesis of disease. Etanercept is a soluble anti-tumor necrosis factor alpha (TNF-alpha) agent licensed for the treatment of active poly-articular juvenile idiopathic arthritis (JIA) in children aged 4 to 17 years who have failed ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology
سال: 2014
ISSN: 1462-0332,1462-0324
DOI: 10.1093/rheumatology/keu125.017